Drug Interactions between doxepin topical and racepinephrine
This report displays the potential drug interactions for the following 2 drugs:
- doxepin topical
- racepinephrine
Interactions between your drugs
doxepin topical racepinephrine
Applies to: doxepin topical and racepinephrine
MONITOR: Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia. In addition, both classes of drugs have been reported to produce electrocardiographic changes including flattening of the T wave and prolongation of the QTc interval, and these effects may be additive during coadministration.
MANAGEMENT: Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.
References (11)
- (2002) "Product Information. Proventil (albuterol)." Schering Corporation
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome
- (2001) "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals
- (2001) "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim
- (2022) "Product Information. Tornalate (bitolterol)." Apothecon Inc
- (2001) "Product Information. Xopenex (levalbuterol)." Sepracor Inc
- (2001) "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals
- (2006) "Product Information. Brovana (arformoterol)." Sepracor Inc
- (2011) "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals
- (2013) "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline
- (2014) "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.